Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen

Molecular Therapy

Volumn 19, Issue 10, 2011, Pages 1793-1801

  King, Gwendalyn D ^a,b   Muhammad, A K M Ghulam ^a,b   Larocque, Daniel ^a,b   Kelson, Kyle R ^a,b   Xiong, Weidong ^a,b   Liu, Chunyan ^a,b   Sanderson, Nicholas S R ^a,b   Kroeger, Kurt M ^a,b   Castro, Maria G ^a,b,c   Lowenstein, Pedro R ^a,b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; FLT3 LIGAND; INFLUENZA VIRUS HEMAGGLUTININ; SITIMAGENE CERADENOVEC; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; BRAIN TUMOR; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; GENE THERAPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOSURVEILLANCE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; RECURRENT DISEASE; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; HUMAN HERPESVIRUS 1;

EID: 85027929861     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.77     Document Type: Article

References (50)

1. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
2. Grossman, SA, Ye, X, Piantadosi, S, Desideri, S, Nabors, LB, Rosenfeld, M et al.; NABTT CNS Consortium. (2010). Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16: 2443-2449.
3. Walker, DG, Laherty, R, Tomlinson, FH, Chuah, T and Schmidt, C (2008). Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci 15: 114-121. (Pubitemid 50017630)
4. Heimberger, AB and Sampson, JH (2009). The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther 9: 1087-1098.
5. Wheeler, CJ and Black, KL (2009). DCVax-Brain and DC vaccines in the treatment of GBM. Expert Opin Investig Drugs 18: 509-519.
6. Schmittling, RJ, Archer, GE, Mitchell, DA, Heimberger, A, Pegram, C, Herndon, JE 2nd et al. (2008). Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 339: 74-81.
7. Heimberger, AB, Sun, W, Hussain, SF, Dey, M, Crutcher, L, Aldape, K et al. (2008). Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro-oncology 10: 98-103. (Pubitemid 351250906)
8. Sampson, JH, Archer, GE, Mitchell, DA, Heimberger, AB and Bigner, DD (2008). Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20: 267-275.
9. Prins, RM, Shu, CJ, Radu, CG, Vo, DD, Khan-Farooqi, H, Soto, H et al. (2008). Antitumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother 57: 1279-1289.
10. Liau, LM, Prins, RM, Kiertscher, SM, Odesa, SK, Kremen, TJ, Giovannone, AJ et al. (2005). Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11: 5515-5525. (Pubitemid 41060828)
11. Wheeler, CJ, Black, KL, Liu, G, Mazer, M, Zhang, XX, Pepkowitz, S et al. (2008). Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68: 5955-5964.
12. Yu, JS, Liu, G, Ying, H, Yong, WH, Black, KL and Wheeler, CJ (2004). Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64: 4973-4979. (Pubitemid 38924545)
13. Sampson, JH, Archer, GE, Mitchell, DA, Heimberger, AB, Herndon, JE 2nd, Lally-Goss, D et al. (2009). An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 8: 2773-2779.
14. De Vleeschouwer, S, Fieuws, S, Rutkowski, S, Van Calenbergh, F, Van Loon, J, Goffin, J et al. (2008). Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14: 3098-3104.
15. Yamanaka, R, Homma, J, Yajima, N, Tsuchiya, N, Sano, M, Kobayashi, T et al. (2005). Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11: 4160-4167. (Pubitemid 40791581)
16. Sampson, JH, Heimberger, AB, Archer, GE, Aldape, KD, Friedman, AH, Friedman, HS et al. (2010). Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 4722-4729.
17. Lowenstein, PR (2010). Cancer vaccines in glioma: how to balance the challenges of small trials, efficiency, and potential adverse events. J Clin Oncol 28: 4670-4673.
18. Lowenstein, PR (2002). Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective. Trends Immunol 23: 23-30. (Pubitemid 34098958)
19. Walker, PR, Calzascia, T, de Tribolet, N and Dietrich, PY (2003). T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev 42: 97-122. (Pubitemid 36549171)
20. Kurpad, SN, Zhao, XG, Wikstrand, CJ, Batra, SK, McLendon, RE and Bigner, DD (1995). Tumor antigens in astrocytic gliomas. Glia 15: 244-256.
21. Saikali, S, Avril, T, Collet, B, Hamlat, A, Bansard, JY, Drenou, B et al. (2007). Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13R2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81: 139-148. (Pubitemid 44963972)
22. Wheeler, CJ, Das, A, Liu, G, Yu, JS and Black, KL (2004). Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10: 5316-5326. (Pubitemid 39100466)
23. Prins, RM, Soto, H, Konkankit, V, Odesa, SK, Eskin, A, Yong, WH et al. (2011). Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17: 1603-1615.
24. de Groot, JF, Fuller, G, Kumar, AJ, Piao, Y, Eterovic, K, Ji, Y et al. (2010). Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-oncology 12: 233-242.
25. Stark, AM, Witzel, P, Strege, RJ, Hugo, HH and Mehdorn, HM (2003). p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme. J Neurol Neurosurg Psychiatr 74: 779-783. (Pubitemid 36628293)
26. Hunter, C, Smith, R, Cahill, DP, Stephens, P, Stevens, C, Teague, J et al. (2006). A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66: 3987-3991.
27. Yip, S, Miao, J, Cahill, DP, Iafrate, AJ, Aldape, K, Nutt, CL et al. (2009). MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15: 4622-4629.
28. Curtin, JF, Liu, N, Candolfi, M, Xiong, W, Assi, H, Yagiz, K et al. (2009). HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 6: e10.
29. Candolfi, M, Yagiz, K, Foulad, D, Alzadeh, GE, Tesarfreund, M, Muhammad, AK et al. (2009). Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 15: 4401-4414.
30. Ali, S, King, GD, Curtin, JF, Candolfi, M, Xiong, W, Liu, C et al. (2005). Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 65: 7194-7204. (Pubitemid 41161250)
31. Candolfi, M, Kroeger, KM, Muhammad, AK, Yagiz, K, Farrokhi, C, Pechnick, RN et al. (2009). Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther 9: 409-421.
32. Yang, J, Sanderson, NS, Wawrowsky, K, Puntel, M, Castro, MG and Lowenstein, PR (2010). Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo. Proc Natl Acad Sci USA 107: 4716-4721.
33. Ghulam Muhammad, AK, Candolfi, M, King, GD, Yagiz, K, Foulad, D, Mineharu, Y et al. (2009). Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 15: 6113-6127.
34. Dewey, RA, Morrissey, G, Cowsill, CM, Stone, D, Bolognani, F, Dodd, NJ et al. (1999). Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 5: 1256-1263. (Pubitemid 29535602)
35. Ali, S, Curtin, JF, Zirger, JM, Xiong, W, King, GD, Barcia, C et al. (2004). Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression. Mol Ther 10: 1071-1084. (Pubitemid 39625251)
36. Curtin, JF, Candolfi, M, Fakhouri, TM, Liu, C, Alden, A, Edwards, M et al. (2008). Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS ONE 3: e1983.
37. Curtin, JF, King, GD, Barcia, C, Liu, C, Hubert, FX, Guillonneau, C et al. (2006). Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol 176: 3566-3577. (Pubitemid 43364004)
38. King, GD, Muhammad, AK, Curtin, JF, Barcia, C, Puntel, M, Liu, C et al. (2008). Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro-oncology 10: 19-31. (Pubitemid 351250897)
39. King, GD, Kroeger, KM, Bresee, CJ, Candolfi, M, Liu, C, Manalo, CM et al. (2008). Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumorinduced behavioral deficits. Mol Ther 16: 682-690. (Pubitemid 351426169)
40. Caton, AJ, Cerasoli, DM and Shih, FF (1998). Immune recognition of influenza hemagglutinin as a viral and a neo-self-antigen. Immunol Res 17: 23-32. (Pubitemid 28073139)
41. Larocque, D, Sanderson, NS, Bergeron, J, Curtin, JF, Girton, J, Wibowo, M et al. (2010). Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proc Natl Acad Sci USA 107: 14443-14448.
42. Sampson, JH, Aldape, KD, Archer, GE, Coan, A, Desjardins, A, Friedman, AH et al. (2011). Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-oncology 13: 324-333.
43. Beckhove, P, Warta, R, Lemke, B, Stoycheva, D, Momburg, F, Schnölzer, M et al. (2010). Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. J Clin Invest 120: 2230-2242.
44. Mitchell, DA, Xie, W, Schmittling, R, Learn, C, Friedman, A, McLendon, RE et al. (2008). Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-oncology 10: 10-18. (Pubitemid 351250896)
45. Black, CA (1999). Delayed type hypersensitivity: current theories with an historic perspective. Dermatol Online J 5: 7.
46. Verhaak, RG, Hoadley, KA, Purdom, E, Wang, V, Qi, Y, Wilkerson, MD et al.; Cancer Genome Atlas Research Network. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
47. Parsons, DW, Jones, S, Zhang, X, Lin, JC, Leary, RJ, Angenendt, P et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
48. Brenner, MK and Heslop, HE (2010). Adoptive T cell therapy of cancer. Curr Opin Immunol 22: 251-257.
49. Southgate, T, Kroeger, KM, Liu, C, Lowenstein, PR and Castro, MG (2008). Gene transfer into neural cells in vitro using adenoviral vectors. Curr Protoc Neurosci Chapter 4: Unit 4.23.
50. Puntel, M, Kroeger, KM, Sanderson, NS, Thomas, CE, Castro, MG and Lowenstein, PR (2010). Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci Chapter 4: Unit 4.24.